Pain-Identifying and Commercializing Market:First-in-Class Innovation - PowerPoint PPT Presentation


PPT – Pain-Identifying and Commercializing Market:First-in-Class Innovation PowerPoint presentation | free to download - id: 702040-MDdkM


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Pain-Identifying and Commercializing Market:First-in-Class Innovation


Big Market Research presents this report which covers and includes a brief introduction to pain, including the different subtypes of pain, pathophysiology, and overview of pharmacotherapy and treatment algorithms. Read The Full Report On : – PowerPoint PPT presentation

Number of Views:18
Slides: 11
Provided by: jamesgorden03
Category: Other


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Pain-Identifying and Commercializing Market:First-in-Class Innovation

Frontier Pharma Pain-Identifying and
Commercializing Market (First-in-Class
  • Large and Innovative Pipeline
  • The active pain pipeline is populated by 796
    products across all stages of development, which
    exhibit a highly diverse range of molecular
    targets. GBI Researchs analyses identified 122
    first-in-class programs in active development,
    constituting 13.6 of the pipeline and acting on
    65 first-in-class molecular targets, indicating a
    high degree of innovation.
  • Despite being mostly distributed in the early
    stages of development, first-in-class innovation
    is particularly concentrated on novel molecular
    targets that are aligned to the central
    sensitization associated with neuropathic pain,
    which is arguably the most debilitating and
    difficult-to-treat type of chronic pain. This
    gives them the potential to transform the future
    market by expanding the range of drug classes.
  • Read The Full Report On http//www.bigmarketrese

Report Description
  • This is in stark contrast to the pain
    therapeutics market, which has been largely
    characterized by only incremental product
    innovation over the last decade, as most market
    segments continue to be dominated by
    long-established active pharmaceutical
    ingredients and the concomitant mechanisms of
    action. Moderate-to-severe pain continues to be
    dominated by opioids that are increasingly being
    reformulated to offer abuse-resistance, while
    mild pain is effectively treated with
    Non-Steroidal Anti-Inflammatory Drugs (NSAID).
  • However, significant unmet needs remain, as
    chronic pain and some neuropathic pain subtypes
    do not respond well to existing therapies, which
    are not adequate to treat associated
    hypersensitization and do not align to the
    underlying molecular pathophysiological
    profile.Encouragingly, these first-in-class
    compounds often target molecules which are
    strongly implicated in pain and its associated
    signaling pathways. Although there are
    significant differentiations in the scientific
    rationale and clinical prospects across these
    first-in-class products, the majority demonstrate
    significant Preclinical evidence and alignment to
    molecular pathophysiological changes

Key Segment
Highly Diversified Range of Innovative Programs
in Early Pipeline and in Granted Patents Pain is
a complex and multifaceted disorder with a
complex interplay between different pathological
processes, and different pain subtypes exhibit
distinct underlying etiologies and
pathophysiologies. While technological advances
and extensive research efforts have furthered the
understanding of these complex underpinnings,
gaps remain. However, these insights have
translated into the expanding pool of novel
therapeutic targets, as reflected by the highly
innovative pipeline. GBI Researchs proprietary
analysis shows that early-stage, first-in-class
programs exhibit a higher level of diversity with
respect to novel therapeutic targets. The
significant diversity in terms of targets is a
reflection of the complex underpinnings of
distinct pain subtypes. Although the pipeline
continues to feature established therapies, the
range of mechanisms of action employed by novel
compounds is extremely diverse, with the vast
majority residing in the Preclinical stage. This
innovation and diversity is maintained throughout
the pipeline from early- to late-stage
development, although the degree of innovation
diminishes from Phase II. Additionally, although
NSAIDs and opioids remain the cornerstone of pain
treatment, GBI Research analysis indicates a
shift towards pain subtypes that are more
difficult to treat.
Key Segment
  • In addition, GBI Researchs comprehensive and
    complementary analysis of granted patents
    highlighted a significant number of
    first-in-class product technologies, many of
    which have not been identified in the pain
    product pipelines or even in pipelines across the
    industry. The distribution of these products
    across the molecular target superfamilies and
    families highlighted that they predominantly
    align with the proportional distribution observed
    across the pain pipeline, with G-protein-coupled
    receptors and enzymes inhibitors constituting the
    two major categories. However, an array of novel
    molecular targets within those groups has been
    identified, which do not present in any pipeline
    or marketed products across the industry. A
    significant degree of innovation has also been
    identified in other molecular target categories.
  • Active Deals Landscape with Numerous Investment
  • The pain deals landscape has been highly active
    over the past eight years, with 261 licensing
    deals and 112 co-development deals. However,
    despite high levels of investment activity, deals
    for first-in-class products have been relatively

Key Market
  • Overall, more than 50 of deals involving
    first-in-class targets were settled in the early
    stages of development, which is a striking
    contrast with non-first-in-class products, which
    are more frequently entered into deals in the
    later stages of development. This reflects
    companies willingness to invest despite the
    high-risk profile of first-in-class products.
  • With 107 first-in-class products available for
    strategic consolidations, a wide variety of
    investment opportunities are available for
    licensing deals or co-development deals in pain.
    This will be encouraged by the growing unmet need
    for chronic pain therapies, and an increased
    understanding of the distinct underlying
    pathophysiologies of distinct pain sub-types,
    allowed by technological advances. Among these,
    some first-in-class products have demonstrated
    promising Preclinical evidence and have
    significant potential to become game-changing
    products, representing high-reward investments.
  • To Get More Details Enquire _at_ http//www.bigmarket

  • The report covers and includes
  • A brief introduction to pain, including the
    different subtypes of pain, pathophysiology, and
    overview of pharmacotherapy and treatment
  • The changing molecular target landscape between
    market and pipeline and particular focal points
    of innovation in the pipeline
  • A comprehensive review of the pipeline for
    first-in-class therapies, analyzed on the basis
    of stage of development, molecule type and
    molecular target
  • Identification and assessment of first-in-class
    molecular targets with a particular focus on
    early-stage programs of which clinical utility
    has yet to be evaluated, as well as literature
    reviews on novel molecular targets
  • Assessment of the licensing and co-development
    deal landscape for pain therapies and
    benchmarking of deals involving first-in-class
    versus non-first-in-class-products

  • The report will assist business development and
    enable marketing executives to strategize their
    product launches, by allowing them to
  • Understand the focal shifts in molecular targets
    in the pain therapeutics pipeline
  • Understand the distribution of pipeline programs
    by phase of development, molecule type and
    molecular target
  • Access a scientific and clinical analysis of
    first-in-class developmental programs for pain,
    benchmarked against non-first-in-class targets.
  • Access a list of the first-in-class therapies
    potentially open to deal-making opportunities

Table Of Content
  • Executive Summary
  • The Case for Innovation
  • Clinical and Commercial Landscape
  • Assessment of Pipeline Product Innovation
  • Pain Patent Analysis
  • First-in-Class Target and Pipeline Program
  • Deals and Strategic Consolidations
  • Appendix
  • Read The Complete TOC _at_ http//www.bigmarketresear

Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
(617) 674-4143 Toll Free 1 (855) 711-1555 Fax
1 (855) 550-5975 Email help_at_bigmarketresearch
.com Web http//